- Tiziana Life Sciences has appointed Professor Christopher McGuigan and Dr Kunwar Shailubhai as non-executive directors and that Andrew Gutmann has resigned from the board.

McGuigan is chairman of Life Sciences Hub Wales Limited, professor of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Sciences, Cardiff University and Director of the National Research Network in Health and Life Sciences of the Welsh Government. He is also on the boards of Synergy Pharmaceuticals and ContraVir Pharmaceuticals, both New York biotechnology companies listed on NASDAQ and on the scientific advisory board of Nucana Biomed, an Edinburgh based company with assets in clinical trials. To date Professor McGuigan has invented three new agents that have reached clinical trials, with peak value of US$3bn. He has over 220 peer reviewed scientific publications with over 100 patents filed.

Shailubhai is a Co-Founder and Chief Scientific Officer of Synergy Pharmaceuticals, Inc. (previously senior vice president), a NASDAQ-listed biotechnology company focusing on innovative therapeutics for treatment of gastrointestinal disorders and diseases, and colon cancer. Dr Shailubhai has held leadership positions at Monsanto Life Sciences Company (St. Louis, MO), where he worked on a number of projects in inflammatory diseases, and Callisto Pharmaceuticals. Dr Shailubhai previously served as a Senior Staff Fellow at the National Institutes of Health and as an Assistant Professor at the University of Maryland. Dr Shailubhai has 17 issued patents, several pending patent applications and 40 research publications in journals of international repute.

Chairman Gabriele Cerrone said: "Christopher and Kunwar are valuable additions to Tiziana's board and I look forward to working with them. They both bring a plethora of knowledge and relevant experience in drug discovery and drug development.

"On behalf of the board I would like to express our thanks to Andrew for the contribution he has made to the company since his appointment. Andrew helped guide the Company through the reverse takeover process that provided the foundation for Tiziana."

At 2:15pm: [LON:TILS] Tiziana Life Sciences Plc Ord 3p share price was 0p at 46.5p

Story provided by